Home・Список акций・REGENXBIO Inc

REGENXBIO Inc

Закрыт

СекторЗдравоохранение

10.3 4.15

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

9.23

Макс.

Ключевые показатели
By Trading Economics
Доход	-23M -90M
Продажи	-24M 6.4M
Прибыль на акцию	-1.72
Рентабельность продаж	-1,408.588
Сотрудники	371
EBITDA	-14M -77M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+160.78% upside

Дивиденды
By Acuity
Следующий отчет о доходах	6 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	101M 622M
Предыдущая цена открытия	6.15
Предыдущая цена закрытия	10.3

Новостные настроения

By Acuity

50%

151 / 340 Рейтинг в Healthcare

REGENXBIO Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 июл. 2026 г., 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 июл. 2026 г., 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 июл. 2026 г., 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 июл. 2026 г., 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 июл. 2026 г., 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 июл. 2026 г., 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 июл. 2026 г., 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 июл. 2026 г., 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 июл. 2026 г., 19:31 UTC

Event

News

Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Сравнение c конкурентами

Изменение цены

REGENXBIO Inc Прогноз

Целевая цена

By TipRanks

160.78% рост

Прогноз на 12 месяцев

Средняя 25.27 USD 160.78%

Максимум 45 USD

Минимум 10 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для REGENXBIO Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

11 ratings

Покупка

Удержание

Продажа

Основано на мнении 11 аналитиков, присваивавших рейтинги акциям REGENXBIO Inc – Данные за последние 3 месяца.

Настроения

By Acuity

151 / 340Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.